PharmaBiome Analysis: $2M Raised
What is PharmaBiome?
PharmaBiome is a pre-clinical stage spinoff from ETH Zurich, focusing on the development of function-based microbiome therapies. The company utilizes proprietary technologies to design and produce bacterial consortia that address specific diseases by reversing dysbiosis. Their approach emphasizes the importance of microbiome function over individual bacterial strains.
Location
Wagistrasse 27, Schlieren 8952, Switzerland
Employees
11-50
Founded
2015
Funding Status
Seed
Product Features & Capabilities
- Function-based microbiome therapies
- Proprietary technologies for bacterial consortia design
- Research collaborations in microbiome R&D
Use Cases
Develop tailored bacterial consortia for inflammatory bowel disease; Engineer microbiome therapies for metabolic disorders; Collaborate with partners for microbiome research; Design function-based therapies for dysbiosis; Produce scalable microbiome solutions for clinical applications
Other Considerations
Collaboration with Ferring for microbiome R&D; Recognized for research published in Gut Microbes; Backed by ETH Zurich expertise in microbiology and biotechnology
See something that needs updating? Suggest edits to this profile.